ClinicalTrials.gg
CompletedNCT01365481Updated Jul 13, 2016Results posted

Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age

A Phase 3 interventional study of Valsartan and amlodipine in Hypertension and Chronic Kidney Disease, sponsored by Novartis Pharmaceuticals. Completed at 28 sites in 10 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-07-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
74th of 139
150 · median 198
Started
2011
with 6 others
Phase 3
53 of 140
none open now
Registered
111th of 140
by date
Lead sponsor
19 of 140
Novartis Pharmaceuticals

Among the 140 studies testing valsartan in Hypertension, this one is the 74th largest by enrollment of the 139 interventional ones that give a count, is one of 7 that started in 2011, is one of 53 in phase 3, and was the 111th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

The purpose of this study is to assess the long-term safety and tolerability profile of valsartan and valsartan-based treatments in children with hypertension, with or without chronic kidney disease.

03

Conditions studied

  • Hypertension
  • Chronic Kidney Disease

Keywords

  • Hypertension, pediatric
  • Hypertension with or without chronic kidney disease
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of hypertension
  • able to swallow a tablet
  • body weight ≥18 kg and ≤160 kg at baseline
  • MSSBP must be ≥ 95th percentile and ≤25% above the 95th percentile for age, gender and height.

Exclusion criteria

Exclusion Criteria:

  • Any physical abnormalities or clinically relevant abnormal laboratory values (other than those relating to renal function) obtained at the screening visit. Including the following:

    1. /SGOT or ALT/SGPT >3 times the upper limit of the reference range. Patients known to have active or chronic hepatitis were excluded.
    2. Total >2 times the upper limit of the reference range
    3. Estimated \<30 mL/min/1.73m² (calculated using Modified Schwartz Formula)
    4. WBC count \<3000/mm³
    5. count \<100,000/mm³
    6. Serum potassium >5.3 mmol/L
    7. \<8 g/dL
  • Uncontrolled diabetes mellitus
  • Unilateral, bilateral and graft renal artery stenosis
  • Current diagnosis of heart failure ( Class II-IV)
  • Patients taking any of the following concomitant medications following screening: Renin-angiotensin receptor(RAAS) blockers other than study drug, Lithium, potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels, Non-steroidal anti-inflammatory drugs (NSAIDS), including selective COX-2 inhibitors, acetylsalicylic acid >3g/day, and non-selective NSAIDs, Antidepressant drugs in the class of Monoamine oxidase (MAO) inhibitors (e.g. phenelzine), Chronic use of stimulant therapy for Attention deficit disorder/attention deficit hyperactivity disorder (ADD/ADHD) -Patients who demonstrate clinically significant abnormalities such as concurrent potentially life threatening arrhythmia or symptomatic arrhythmia and patients with second or third degree heart block without a pacemaker.
  • Coarctation of the aorta with a gradient of >=30 mmHg
  • Previous solid organ transplantation except renal transplantation.
  • Patients known to be positive for the (HIV)
  • Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of the study drug
  • Known or suspected to the study drug, including severe hepatic impairment, biliary cirrhosis, cholestasis and history of allergy to ARBs and/or angiotensin-converting enzymes (ACE) and/or Direct Renin Inhibitors (DRIs)
  • History of of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or , with the exception of localized basal cell carcinoma of the skin.
  • History or evidence of drug or alcohol abuse within the last 12 months.
  • Female patients of , defined as all female patients physiologically capable of becoming pregnant, unless they are willing to use highly effective during the study
  • Pregnant or nursing (lactating) female patients
  • Participation in any drug study within 30 days prior to screening or within 5 elimination half-lives of the study drug prior to screening, or whichever is longer.
  • History of to the study drug or to drugs of similar chemical classes.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    valsartan

    Valsartan starting dose: ≥18 kg to \<35 kg is 40 mg, ≥35 kg to \<80 kg is 80 mg, ≥80 kg to ≤160 kg is 160 mg for 1 week then Valsartan maintenance dose: ≥18 kg to \<35 kg is 80 mg, ≥35 kg to \<80 kg is 160 mg, ≥80 kg to ≤160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study.

    Drug: Valsartan · Drug: amlodipine · Drug: Hydrochlorothiazide

Interventions

  • week 1: 40/80/160 week 2-78: 80/160/320mg, oral, by mouth, once daily

    Also known as: VAL489

  • added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose

  • added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose

    Also known as: HCTZ

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF)

    Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 2 to 3 minute intervals and the mean of three sSBP measurements were used as the average sitting office blood pressure for that visit.

    Time frame: Baseline, End Point (Week 78 or Last observation carried forward (LOCF)

  2. Change From Baseline in Mean Sitting Diastolic Blood Pressure (MsDBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF)

    Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 2 to 3 minute intervals and the mean of three sDBP measurements were used as the average sitting office blood pressure for that visit.

    Time frame: Baseline, End Point (Week 78 or Last observation carried forward (LOCF)

Secondary outcomes

  1. Number of Participants With MSSBP, MSDBP and (MSSBP and MSDBP Combined) < 95th Percentile for Gender, Age, and Height

    Number of Participants with Mean sitting systolic (MSSBP) and mean sitting diastolic(MSDBP) blood pressure and both combined less than the 95th percentile for age, gender and height

    Time frame: End Point (Week 78 or Last observation carried forward (LOCF)

  2. Percentage of Chronic Kidney Disease (CKD) Patients Who Had >=50% Reduction in Urine Albumin/Creatinine Ratio (UACR) From Baseline to End Point

    Percentage of Patients with CKD who had Urine albumin creatinine reduction \>/= 50% from baseline

    Time frame: Baseline, End Point (Week 78 or Last observation carried forward (LOCF)

  3. Percentage of Chronic Kidney Disease (CKD) Patients Who Had Estimated Glomerular Filtration Rate (eGFR) Decrease > 25 % From Baselinefrom Baseline to End Point

    Percentage of Patients with CKD who had eGFR decrease \> 25 % from Baseline

    Time frame: Baseline, End Point (Week 78 or Last observation carried forward (LOCF)

07

Results

Posted Apr 21, 2016

Participant flow

A 1 arm study of valsartan but with 2 groups for analyses. The valsartan +antihypertensive group includes the patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study.

Participant flow — Overall Study
MilestoneCKD Patients: Valsartan + Antihypertensive GroupCKD Patients: Valsartan AloneNon-CKD Patients: Valsartan + Antihypertensive GroupNon-CKD Patients: Valsartan Alone
Started23521857
Completed16371450
Not completed71547
Withdrew: Adverse event6902
Withdrew: Withdrawal by subject0211
Withdrew: Lost to follow-up1123
Withdrew: Abnormal laboratory value(s)0100
Withdrew: Administrative problems0100
Withdrew: Protocol deviation0101
Withdrew: Unsatisfactory therapeutic effect0010

Outcome measures

PrimaryChange From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF)

Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 2 to 3 minute intervals and the mean of three sSBP measurements were used as the average sitting office blood pressure for that visit.

Time frame:
Baseline, End Point (Week 78 or Last observation carried forward (LOCF)
Reported as:
Mean · millimeter(s) of mercury (mmHg)
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF)
millimeter(s) of mercury (mmHg)Valsartan + Antihypertensive GroupValsartan Alone
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF)-13.3 ± 13.69-15.5 ± 13.35
SecondaryNumber of Participants With MSSBP, MSDBP and (MSSBP and MSDBP Combined) < 95th Percentile for Gender, Age, and Height

Number of Participants with Mean sitting systolic (MSSBP) and mean sitting diastolic(MSDBP) blood pressure and both combined less than the 95th percentile for age, gender and height

Time frame:
End Point (Week 78 or Last observation carried forward (LOCF)
Reported as:
Number · Number of Participants
Number of Participants With MSSBP, MSDBP and (MSSBP and MSDBP Combined) < 95th Percentile for Gender, Age, and Height
Number of ParticipantsValsartan + Antihypertensive GroupValsartan Alone
MSSBP (n=39, 105)2390
MSDBP (n=28, 51)2047
MSSBP and MSDBP combined (n=40, 105)2288
SecondaryPercentage of Chronic Kidney Disease (CKD) Patients Who Had >=50% Reduction in Urine Albumin/Creatinine Ratio (UACR) From Baseline to End Point

Percentage of Patients with CKD who had Urine albumin creatinine reduction \>/= 50% from baseline

Time frame:
Baseline, End Point (Week 78 or Last observation carried forward (LOCF)
Reported as:
Number · Percentage of patients
Percentage of Chronic Kidney Disease (CKD) Patients Who Had >=50% Reduction in Urine Albumin/Creatinine Ratio (UACR) From Baseline to End Point
Percentage of patientsValsartan + Antihypertensive GroupValsartan Alone
Percentage of Chronic Kidney Disease (CKD) Patients Who Had >=50% Reduction in Urine Albumin/Creatinine Ratio (UACR) From Baseline to End Point50.0 ± 404.0841.9 ± 138.66
PrimaryChange From Baseline in Mean Sitting Diastolic Blood Pressure (MsDBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF)

Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 2 to 3 minute intervals and the mean of three sDBP measurements were used as the average sitting office blood pressure for that visit.

Time frame:
Baseline, End Point (Week 78 or Last observation carried forward (LOCF)
Reported as:
Mean · millimeter(s) of mercury (mmHg)
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MsDBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF)
millimeter(s) of mercury (mmHg)Valsartan + Antihypertensive GroupValsartan Alone
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MsDBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF)-10.3 ± 11.94-10.8 ± 11.45
SecondaryPercentage of Chronic Kidney Disease (CKD) Patients Who Had Estimated Glomerular Filtration Rate (eGFR) Decrease > 25 % From Baselinefrom Baseline to End Point

Percentage of Patients with CKD who had eGFR decrease \> 25 % from Baseline

Time frame:
Baseline, End Point (Week 78 or Last observation carried forward (LOCF)
Reported as:
Number · Percentage of patients
Percentage of Chronic Kidney Disease (CKD) Patients Who Had Estimated Glomerular Filtration Rate (eGFR) Decrease > 25 % From Baselinefrom Baseline to End Point
Percentage of patientsValsartan + Antihypertensive GroupValsartan Alone
Percentage of Chronic Kidney Disease (CKD) Patients Who Had Estimated Glomerular Filtration Rate (eGFR) Decrease > 25 % From Baselinefrom Baseline to End Point30.4 ± 404.0827.5 ± 138.66

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valsartan + Antihypertensive Group—8/41 (19.5%)34/41 (82.9%)
Valsartan Alone—7/109 (6.4%)68/109 (62.4%)
CKD Patients: Valsartan + Antihypertensive Group—7/23 (30.4%)18/23 (78.3%)
CKD Patients: Valsartan Alone—4/52 (7.7%)36/52 (69.2%)
Non-CKD Patients: Valsartan + Antihypertensive Group—1/18 (5.6%)16/18 (88.9%)
Non-CKD Patients: Valsartan Alone—3/57 (5.3%)32/57 (56.1%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventValsartan + Antihypertensive GroupValsartan AloneCKD Patients: Valsartan + Antihypertensive GroupCKD Patients: Valsartan AloneNon-CKD Patients: Valsartan + Antihypertensive GroupNon-CKD Patients: Valsartan Alone
Lupus nephritisRenal and urinary disorders3/411/1093/231/520/180/57
HypertensionVascular disorders1/410/1090/230/521/180/57
Febrile neutropeniaBlood and lymphatic system disorders1/410/1091/230/520/180/57
Oesophageal polypGastrointestinal disorders1/410/1091/230/520/180/57
Face oedemaGeneral disorders1/410/1091/230/520/180/57
Oedema peripheralGeneral disorders1/410/1091/230/520/180/57
GastroenteritisInfections and infestations1/410/1091/230/520/180/57
PneumoniaInfections and infestations1/411/1091/231/520/180/57
Glomerular filtration rate decreasedInvestigations1/410/1091/230/520/180/57
SynovitisMusculoskeletal and connective tissue disorders1/410/1091/230/520/180/57
Most frequent other events
Showing 10 of 46
Most frequent other events
EventValsartan + Antihypertensive GroupValsartan AloneCKD Patients: Valsartan + Antihypertensive GroupCKD Patients: Valsartan AloneNon-CKD Patients: Valsartan + Antihypertensive GroupNon-CKD Patients: Valsartan Alone
CoughRespiratory, thoracic and mediastinal disorders18/4118/10912/2312/526/186/57
PyrexiaGeneral disorders12/4118/1098/2312/524/186/57
HeadacheNervous system disorders14/4123/1098/2311/526/1812/57
NasopharyngitisInfections and infestations11/4122/1097/2314/524/188/57
Upper respiratory tract infectionInfections and infestations2/4117/1091/2312/521/185/57
DizzinessNervous system disorders8/4117/1094/236/524/1811/57
VomitingGastrointestinal disorders5/414/1094/233/521/181/57
RhinorrhoeaRespiratory, thoracic and mediastinal disorders4/413/1093/232/521/181/57
Abdominal painGastrointestinal disorders4/417/1092/234/522/183/57
InfluenzaInfections and infestations3/411/1091/230/522/181/57

Baseline characteristics

Age, Continuous
Age, Continuous(years)CKD Patients: Valsartan + Antihypertensive GroupCKD Patients: Valsartan AloneNon-CKD Patients: Valsartan + Antihypertensive GroupNon-CKD Patients: Valsartan AloneTotal
Mean12.90 ± 3.3512.30 ± 3.2013.79 ± 2.6414.37 ± 2.8313.36 ± 3.130
Age, Customized
Age, Customized(participants)CKD Patients: Valsartan + Antihypertensive GroupCKD Patients: Valsartan AloneNon-CKD Patients: Valsartan + Antihypertensive GroupNon-CKD Patients: Valsartan AloneTotal
6 - 11 years102231045
12 - 17 years13301547105
Sex: Female, Male
Sex: Female, Male(Participants)CKD Patients: Valsartan + Antihypertensive GroupCKD Patients: Valsartan AloneNon-CKD Patients: Valsartan + Antihypertensive GroupNon-CKD Patients: Valsartan AloneTotal
Female121632051
Male1136153799
08

Study locations

28 sites
  • Novartis Investigative Site
    Bucaramanga, Santander 0001, Colombia
  • Novartis Investigative Site
    Barranquilla, Colombia
  • Novartis Investigative Site
    Cali, Colombia
  • Novartis Investigative Site
    Helsinki, 00029, Finland
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Cottbus, 03048, Germany
  • Novartis Investigative Site
    Freiburg, 79106, Germany
  • Novartis Investigative Site
    Homburg, 66421, Germany
  • Novartis Investigative Site
    Rostock, 18107, Germany
  • Novartis Investigative Site
    Guatemala City, 01010, Guatemala
  • Novartis Investigative Site
    Seoul, Korea 03080, Korea, Republic of
  • Novartis Investigative Site
    Manila, 1000, Philippines
  • Novartis Investigative Site
    Quezon City, 1100, Philippines
  • Novartis Investigative Site
    Quezon City, 1101, Philippines
  • Novartis Investigative Site
    Warszawa, 04-154, Poland
  • Novartis Investigative Site
    Cluj-Napoca, Jud Cluj, Romania
  • Novartis Investigative Site
    Tg. Mures, jud Mures 540104, Romania
  • Novartis Investigative Site
    Timisoara, jud. Timis 300011, Romania
  • Novartis Investigative Site
    Bucuresti, 041451, Romania
  • Novartis Investigative Site
    Bucuresti, 20395, Romania
  • Novartis Investigative Site
    Iasi, 700309, Romania
  • Novartis Investigative Site
    Kazan, 420012, Russian Federation
  • Novartis Investigative Site
    Moscow, 119991, Russian Federation
  • Novartis Investigative Site
    Moscow, 125315, Russian Federation
  • Novartis Investigative Site
    Moscow, 127412, Russian Federation
  • Novartis Investigative Site
    Voronezh, 394036, Russian Federation
  • Novartis Investigative Site
    Singapore, 119074, Singapore
  • Novartis Investigative Site
    Singapore, 229899, Singapore
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2011
First posted
Jun 3, 2011
Start
Aug 2011
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results first posted
Apr 21, 2016
Last update
Jul 13, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01365481
Responsible party
Sponsor
First posted
Jun 3, 2011
Start date
Aug 2011
Primary completion
Sep 2015
Completion
Sep 2015
Results posted
Apr 21, 2016
Last update
Jul 13, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valsartan

Start the discussion